Journals / Klinik Psikofarmakoloji Bülteni / 2010 / Cilt: 20 - Sayı: 3

Bir ergende atomoksetin kullanımı ile ilişkili saç dökülmesi: Bir olgu bildirimi

Atomoxetine-related hair loss in a teenager: A case report

Pages
258–260
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To our knowledge, this is the second report of a causal connection between atomoxetine intake and hair loss.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atomoxetine, a selective norepinephrine inhibitor, was introduced as a safe non-stimulant alternative treatment for attention deficit hyperactivity disorder.
📊
Key Findings & Data:In the clinical practice common side effects of atomoxetine are headache, abdominal pain, decreased appetite, fatigue, nausea, vomiting and dizziness.
💡
Conclusion & Impact:To our knowledge, this is the second report of a causal connection between atomoxetine intake and hair loss.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atomoxetine, a selective norepinephrine inhibitor, was introduced as a safe non-stimulant alternative treatment for attention deficit hyperactivity disorder. In the clinical practice common side effects of atomoxetine are headache, abdominal pain, decreased appetite, fatigue, nausea, vomiting and dizziness. Here, we present an adolescent male who developed diffuse alopecia under atomoxetine treatment with no personal and family history of alopecia. To our knowledge, this is the second report of a causal connection between atomoxetine intake and hair loss.

Özet

Atomoksetin dikkat eksikliği hiperaktivite bozukluğu tedavisinde stimülan olmayan, noradrenalin geri alım inhibisyonu yapan yeni bir tedavi seçeneğidir. Atomoksetinin klinik kullanımı sırasında en çok karşılaşılan yan etkiler; baş ağrısı, karın ağrısı, iştah azalması, halsizlik, bulantı, kusma ve baş dönmesidir. Bu olgu sunumunda, atomoksetin başlanması ardından özgeçmişinde ve aile öyküsünde olmadığı halde, yaygın saç dökülmesi gözlenen bir erkek ergeni bildiriyoruz. Bildiğimiz kadarıyla, bu olgu sunumu atomoksetin ile ilişkili saç dökülmesi bildiren ikinci bildirimdir.

🔖

Cite This Article

YALÇIN, Ö., CEYLAN, M. F. (2022). Bir ergende atomoksetin kullanımı ile ilişkili saç dökülmesi: Bir olgu bildirimi. Klinik Psikofarmakoloji Bülteni, Cilt: 20 - Sayı: 3, 258–260. https://ajindex.com/articles/571951

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491-497
  2. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002; 27: 389-395
  3. Blaukenship HL. Drugs and alopecia. Australas J Dermatol 1983; 24:100-104
  4. Gautam M. Alopecia due to psychotropic medications. Ann Pharmacoter 1999; 33(Suppl5): S631-S637
  5. Warnock JK. Psychotropic medications and drug-related alopecia. Psychosomatics 1991; 17: 334-341
  6. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-988
  7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994
  8. Anderson I. Alopecia areata; a clinical study. BMJ 1980; 2: 250
  9. Brodin M. Drug-related alopecia. Dermatol Clin 1987; 5: 571-579
  10. McKinney PA, Finkenbine RD, DeVane CL. Alopecia and mood stabilizer therapy. Ann Clin Psychiatry 1996; 8:183-185
  11. Orwin A: Hair loss following lithium therapy. Br J Dermatol 1983; 108:503-504
  12. Khan TA, Sheng H, Mercke YK., Lippmann SB. Divalproexinduced alopecia: a case report. Psychiatr Serv 1999; 50(11):1500 13. O’Bryan EC, Albanese RP. A case report of fluoxetine- and venlafaxine-induced hair loss. Prim Care Companion J Clin Psychiatry 2004; 6:181
  13. Uzun Ö, Cansever A, Özgen F. Hair loss due to sertraline use: a case report. Klinik Psikofarmakoloji Bülteni/Bulletin of Clinical Psychopharmacology 2003; 13:27-29
  14. Frances C, Hoizey G, Millart H, and Trenque T. Paediatric methylphenidate (Ritalin) restrictive conditions of prescription in France. Br J Clin Pharmacol 2004; 57:115-116
  15. Teo S, Stirling D, Thomas S, Hoberman A, Kiorpes A, Khetani V. A 90-day oral gavage toxicity study of D-methylphenidate and D, L-methylphenidate in Sprague-Dawley rats. Toxicology 2002; 179:183-196
  16. Voron DA. Alopecia and amphetamine use. JAMA. 1988; 260:183-184
  17. Fiedler VC, Gray AC. Disorders of Hair Growth: Diagnosis and Treatment. Diffuse alopecia: telogen hair loss. In: Olsen EA (ed.) 2nd ed. New York, NY: McGraw-Hill Publishing, 2003: 303–320
  18. Rook A, Dawber R. Diffuse alopecia: endocrine, metabolic and chemical influences on the follicular cycle. In: Diseases of the Hair and Scalp. Oxford, UK: Blackwell Science Publication